Asset Details
Do you wish to reserve the book?
Beneficial impact of spironolactone in diabetic nephropathy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Beneficial impact of spironolactone in diabetic nephropathy
Do you wish to request the book?
Beneficial impact of spironolactone in diabetic nephropathy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Beneficial impact of spironolactone in diabetic nephropathy
2005
Overview
Beneficial impact of spironolactone in diabetic nephropathy.
Aldosterone has been suggested to play a role in the initiation and progression of diabetic nephropathy. Currently recommended treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers [renin-angiotensin system (RAS) blockade] does not suppress circulating aldosterone sufficiently. We therefore aimed to evaluate the short-term effect of aldosterone antagonism with spironolactone on albuminuria and blood pressure in diabetic nephropathy.
Twenty Caucasian type 1 diabetic patients with persistent macroalbuminuria despite antihypertensive treatment, including RAS blockade, completed this double-masked, randomized cross-over trial. Patients were treated in random order with spironolactone 25mg once daily and matched placebo for two months, respectively, on top of usual antihypertensive treatment. After each treatment period albuminuria, 24-hour blood pressure, and glomerular filtration rate (GFR) were determined.
Spironolactone on top of usual antihypertensive treatment induced a 30% (95% CI 17 to 41) reduction in albuminuria from [geometric mean (95% CI)] 831 (624 to 1106) mg/24-hour on placebo treatment (P < 0.001), and a reduction in fractional albumin clearance of 35% (20 to 46, P < 0.001). Twenty-four-hour blood pressure showed an insignificant reduction of [mean reduction (95% CI)] 8 (-1 to 17)/3 (-0.2 to 7) mm Hg (P < 0.10). There was an insignificant reversible reduction in GFR during treatment with spironolactone. On spironolactone treatment, one patient was excluded due to hyperkalemia (plasma potassium 5.7mmol/L) and one due to orthostatic dizziness. Otherwise treatment was well tolerated.
Our results suggest that spironolactone treatment on top of recommended antihypertensive treatment reduces blood pressure and may offer additional renoprotection in type 1 diabetic patients with diabetic nephropathy.
Publisher
Elsevier Inc,Nature Publishing,Elsevier Limited
Subject
/ Biological and medical sciences
/ diabetes
/ Diabetes Mellitus, Type 1 - complications
/ Diabetes. Impaired glucose tolerance
/ Diabetic Nephropathies - drug therapy
/ Endocrine pancreas. Apud cells (diseases)
/ Etiopathogenesis. Screening. Investigations. Target tissue resistance
/ Female
/ Humans
/ Hypertension, Renal - drug therapy
/ Kidneys
/ Male
/ Mineralocorticoid Receptor Antagonists - administration & dosage
/ Mineralocorticoid Receptor Antagonists - adverse effects
/ Nephrology. Urinary tract diseases
/ Spironolactone - administration & dosage
/ Spironolactone - adverse effects
/ Urinary system involvement in other diseases. Miscellaneous
